AP389A - Indol-2-one compounds and their preparation. - Google Patents

Indol-2-one compounds and their preparation. Download PDF

Info

Publication number
AP389A
AP389A APAP/P/1992/000464A AP9200464A AP389A AP 389 A AP389 A AP 389A AP 9200464 A AP9200464 A AP 9200464A AP 389 A AP389 A AP 389A
Authority
AP
ARIPO
Prior art keywords
lower alkyl
ethyl
compound
phenylmethyl
indol
Prior art date
Application number
APAP/P/1992/000464A
Other languages
English (en)
Other versions
AP9200464A0 (en
Inventor
Bernard Robin Boar
Alan John Cross
Original Assignee
Ab Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Astra filed Critical Ab Astra
Publication of AP9200464A0 publication Critical patent/AP9200464A0/xx
Application granted granted Critical
Publication of AP389A publication Critical patent/AP389A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1992/000464A 1991-12-18 1992-12-14 Indol-2-one compounds and their preparation. AP389A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9103752A SE9103752D0 (sv) 1991-12-18 1991-12-18 New compounds

Publications (2)

Publication Number Publication Date
AP9200464A0 AP9200464A0 (en) 1993-01-31
AP389A true AP389A (en) 1995-08-02

Family

ID=20384648

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1992/000464A AP389A (en) 1991-12-18 1992-12-14 Indol-2-one compounds and their preparation.

Country Status (23)

Country Link
US (1) US5585378A (is)
EP (1) EP0624156A1 (is)
JP (1) JPH07502272A (is)
CN (1) CN1034939C (is)
AP (1) AP389A (is)
AU (1) AU675055B2 (is)
BG (1) BG98815A (is)
CA (1) CA2124826A1 (is)
CZ (1) CZ146694A3 (is)
EE (1) EE9400428A (is)
FI (1) FI942913A7 (is)
HU (1) HUT69704A (is)
IL (1) IL104107A0 (is)
IS (1) IS3958A (is)
MX (1) MX9207382A (is)
NO (1) NO942316L (is)
PL (1) PL170736B1 (is)
SE (1) SE9103752D0 (is)
SI (1) SI9200405A (is)
SK (1) SK278321B6 (is)
TN (1) TNSN92114A1 (is)
WO (1) WO1993012085A1 (is)
ZA (1) ZA929700B (is)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620973A (en) * 1993-11-30 1997-04-15 Takeda Chemical Industries, Ltd. Tetracyclic condensed heterocyclic compounds and their use
SE9504267D0 (sv) * 1995-11-29 1995-11-29 Astra Ab New therapeutic use
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
WO1998007431A1 (en) * 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
WO1998008816A1 (en) * 1996-08-26 1998-03-05 Meiji Seika Kaisha, Ltd. Oxindole derivatives and psychotropic drugs
KR20010041625A (ko) * 1998-03-06 2001-05-25 아스트라제네카 악티에볼라그 신규 용도
GB9810886D0 (en) * 1998-05-13 1998-07-22 Lilly Industries Ltd Pharmaceutical compounds
GB9820489D0 (en) * 1998-09-22 1998-11-11 Steiger Malcolm J Compounds for improved treatment of parkinson's disease
EP1891954A3 (en) 1998-09-30 2009-01-14 Takeda Pharmaceutical Company Limited Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
AU2001249091A1 (en) * 2000-03-03 2001-09-17 Eisai Co. Ltd. Novel methods using cholinesterase inhibitors
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CN1317276C (zh) * 2000-09-29 2007-05-23 中国科学院上海药物研究所 一类吲哚基哌啶类化合物及其制备方法和用途
JP2004529110A (ja) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ 脈管損傷活性を有するインドール誘導体
US6770638B2 (en) 2001-04-20 2004-08-03 Spectrum Pharmaceuticals, Inc. Tetrahydroindolone and purine derivatives linked to arylpiperazines
EP1764134B1 (en) * 2001-07-30 2009-01-28 Spectrum Pharmaceuticals, Inc. Purine derivatives linked to arylpiperazines
DE60223031T2 (de) * 2001-07-30 2008-07-24 Spectrum Pharmaceuticals, Inc., Irvine Arylpiperazin gebundene tetrahydroindolonderivate
EP1715921B1 (en) * 2003-09-25 2013-04-24 Abraxis BioScience, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
MY150958A (en) * 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
EP1919497B1 (en) 2005-07-22 2020-02-12 The Board of Trustees of the Leland Stanford Junior University Light-activated cation channel and uses thereof
US10052497B2 (en) 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US8398692B2 (en) 2007-01-10 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US8401609B2 (en) 2007-02-14 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
US10035027B2 (en) 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
WO2009062134A1 (en) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
BRPI0911448A2 (pt) 2008-04-23 2019-02-26 The Board Of Trustees For The Leland Stanford Junior University sistemas, métodos e composições para simulação óticas de células alvo
CA2726128C (en) 2008-05-29 2016-10-18 The Board Of Trustees Of The Leland Stanford Junior University Cell line, system and method for optical control of secondary messengers
US10711242B2 (en) 2008-06-17 2020-07-14 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for controlling cellular development
WO2010006049A1 (en) 2008-07-08 2010-01-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
WO2010090680A1 (en) * 2008-12-15 2010-08-12 Wyeth Llc Substituted oxindole cb2 agonists
EP2547762B1 (en) 2010-03-17 2018-04-25 The Board of Trustees of the Leland Stanford Junior University Light-sensitive ion-passing molecules
BR112012024380A2 (pt) 2010-03-25 2015-09-15 Glaxosmithkline Llc compostos químicos
CN101863823B (zh) * 2010-06-03 2012-02-08 山东大学 吲哚二酮类化合物及其扩环衍生物、制备方法及应用
CN103313752B (zh) 2010-11-05 2016-10-19 斯坦福大学托管董事会 用于光遗传学方法的光的上转换
EP2635295B1 (en) 2010-11-05 2017-12-20 The Board of Trustees of the Leland Stanford Junior University Control and characterization of memory function
CA2816968C (en) 2010-11-05 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Optically-controlled cns dysfunction
CA2816990A1 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Stabilized step function opsin proteins and methods of using the same
CN106947741A (zh) 2010-11-05 2017-07-14 斯坦福大学托管董事会 光活化嵌合视蛋白及其使用方法
JP6355335B2 (ja) * 2010-11-05 2018-07-11 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 報酬関連行動の光遺伝学的制御
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
CN107936097A (zh) 2011-12-16 2018-04-20 斯坦福大学托管董事会 视蛋白多肽及其使用方法
US20140024701A1 (en) 2012-02-21 2014-01-23 Circuit Therapeutics, Inc. Compositions and Methods for Treating Neurogenic Disorders of the Pelvic Floor
CN103006642B (zh) * 2013-01-04 2014-10-22 中国药科大学 一类炔亚甲基吲哚-2-酮类衍生物的用途
CN105246550A (zh) 2013-03-15 2016-01-13 小利兰·斯坦福大学托管委员会 行为状态的光遗传学控制
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
WO2014179331A2 (en) 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Devices, systems and methods for optogenetic modulation of action potentials in target cells
CN104530065A (zh) * 2013-05-13 2015-04-22 江西科技师范大学 1-n酰基取代吲哚酮衍生物的应用
CN103242332B (zh) * 2013-05-13 2015-11-04 江西科技师范大学 1-n酰基取代吲哚酮衍生物
AU2014306679A1 (en) 2013-08-14 2016-03-10 Circuit Therapeutics, Inc. Compositions and methods for controlling pain
CN103420941B (zh) * 2013-08-26 2015-09-23 浙江大学 2-甲氧基苯基-二甲胺基甲酸酯衍生物及制备和用途
US10568516B2 (en) 2015-06-22 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture
CN117624015B (zh) * 2023-12-06 2024-08-16 广东医科大学 一种取代靛红-褪黑激素衍生物及其制备方法和应用
CN120399173A (zh) * 2024-04-29 2025-08-01 西湖大学 基于聚芳基靛红的阳离子聚合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002725A1 (fr) * 1989-08-25 1991-06-07 Syntheses Et Recherches Derives de la 5-amino-1,2,3,4-tetrahydro-acridine et applications comme medicaments

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3573310A (en) * 1967-09-28 1971-03-30 Miles Lab 1-substituted derivatives of 2-indolinone
US3635976A (en) * 1967-12-20 1972-01-18 Pennwalt Corp 1 - heterocyclic alkyl-1 2 3 4-tetrahydroquinazolinones and analgesic intermediates thereof
DE2123923A1 (de) * 1971-05-14 1972-11-23 Boehringer Mannheim Gmbh, 6800 Mannheim 4-eckige Klammer auf omega- (Flavon-7yl-oxy) -alkyl eckige Klammer zu -pigerazin-Derivate und Verfahren zu ihrer Herstellung
GR65270B (en) * 1978-10-10 1980-07-31 Fujisawa Pharmaceutical Co Isatin derivatives and processes for the preparation thereof
US4692448A (en) * 1984-11-20 1987-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Bis(arylpiperazinyl)sulfur compounds
JPS62294654A (ja) * 1986-06-13 1987-12-22 Kissei Pharmaceut Co Ltd イサチン誘導体
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
SE9302080D0 (sv) * 1993-06-16 1993-06-16 Ab Astra New compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002725A1 (fr) * 1989-08-25 1991-06-07 Syntheses Et Recherches Derives de la 5-amino-1,2,3,4-tetrahydro-acridine et applications comme medicaments

Also Published As

Publication number Publication date
BG98815A (bg) 1995-05-31
FI942913L (fi) 1994-08-17
AU675055B2 (en) 1997-01-23
IS3958A (is) 1993-06-19
PL170736B1 (pl) 1997-01-31
SI9200405A (en) 1993-06-30
SK278321B6 (en) 1996-10-02
NO942316D0 (no) 1994-06-17
AU3175993A (en) 1993-07-19
HUT69704A (en) 1995-09-28
CN1034939C (zh) 1997-05-21
EP0624156A1 (en) 1994-11-17
CZ146694A3 (en) 1995-06-14
SE9103752D0 (sv) 1991-12-18
NO942316L (no) 1994-06-17
CN1079464A (zh) 1993-12-15
MX9207382A (es) 1993-07-01
FI942913A0 (fi) 1994-06-17
AP9200464A0 (en) 1993-01-31
WO1993012085A1 (en) 1993-06-24
SK73494A3 (en) 1995-03-08
IL104107A0 (en) 1993-05-13
EE9400428A (et) 1996-04-15
TNSN92114A1 (fr) 1993-06-08
HU9401844D0 (en) 1994-09-28
US5585378A (en) 1996-12-17
CA2124826A1 (en) 1993-06-24
FI942913A7 (fi) 1994-08-17
ZA929700B (en) 1993-08-10
JPH07502272A (ja) 1995-03-09

Similar Documents

Publication Publication Date Title
AP389A (en) Indol-2-one compounds and their preparation.
US4954503A (en) 3-(1-substituted-4-piperazinyl)-1H-indazoles
EP1745040B9 (en) Azabicyclo(3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
EP1392316B1 (en) Benzo[d]azepine derivatives as 5-ht6 receptor antagonists.
US5077293A (en) 1-indolyalkyl-4-(alkoxypyrimidinyl)piperazines
AU7010894A (en) 1-substituted isatin and oxindole derivatives as inhibitors of acetylcholinesterase
AU646679B2 (en) Novel 3-arylindole and 3-arylindazole derivatives
HUT62573A (en) Process for producing piperidine derivatives and pharmaceutical compositions comprising such compounds
NO300809B1 (no) Tricykliske kondenserte heterocykliske forbindelser og deres anvendelse
US7803820B2 (en) 3-triazolylthiaalkyl-3-azabicyclo (3-1-O) hexanes and their use as dopamine D3 receptor ligands
EP1891056B1 (en) Novel compounds
JP2011515359A (ja) 治療用トリアゾールアミド誘導体
JP2006503056A (ja) ヒスタミンｈ３受容体アンタゴニスト、その製造および治療用使用
US20090306144A1 (en) Pyridine derivatives of alkyl oxindoles as 5-ht7 receptor active agents
JPH0733744A (ja) インダゾール誘導体およびその塩
AU2005240843B2 (en) Piperazine derivatives of alkyl oxindoles
AU761122B2 (en) Aryl-(4-flouro-4-((2-pyridin-2-yl-ethylamino)-methyl)- piperidin-1-yl)-methanone derivatives as 5-HT1 receptor antagonists
TW308587B (is)
HK1103016B (en) Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors